B R I E F C O M M U N I C AT I O N S © 2009 Nature America, Inc. All rights reserved. Alefacept promotes co-stimulation blockade

First Page		Document Content
Date: 2010-02-12 10:42:35 Anatomy B7 T helper cell CTLA-4 Transplant rejection Interleukin Alefacept CD86 CD8+ cell T cells Immune system Biology		B R I E F C O M M U N I C AT I O N S © 2009 Nature America, Inc. All rights reserved. Alefacept promotes co-stimulation blockade Add to Reading List Source URL: www.nature.com Download Document from Source Website File Size: 462,12 KB Share Document on Facebook

	------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme DocID: 1m0Le - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COSENTYX safely and effectively. See full prescribing information for COSENTYX. ---------------------------------CO DocID: UPmN - View Document
	Horizon Scanning Technology Prioritising Summary Home ultraviolet B (UVB) phototherapy for the treatment of severe psoriasis March 2010 DocID: SMK1 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: RJk3 - View Document
	achanA September 12, 2007 Astellas Initiates Phase II Clinical Trials for Immunosuppressant, ASP0485 DocID: M3jp - View Document